Solbec Pharmaceuticals Limited has announced its lead anti-cancer compound Coramsine has received orphan drug designation from the US Food and Drug Administration. The compound is used for the treatment of metastatic renal cell carcinoma. Solbec's strategy is to market Coramsine within 3 - 5 years.
© Business News 2017. You may share content using the tools provided but do not copy and redistribute.